{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:26:47Z","timestamp":1780478807341,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274379"],"award-info":[{"award-number":["82274379"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QH102"],"award-info":[{"award-number":["ZR2024QH102"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40120-024-00684-9","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:09:48Z","timestamp":1733940588000},"page":"491-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Various Intravenous Thrombolytics for Acute Ischemic Stroke (AIS) at Various Dosages: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Yibin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-8234","authenticated-orcid":false,"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"issue":"10446","key":"684_CR1","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1016\/S0140-6736(24)00642-1","volume":"403","author":"NA Hilkens","year":"2024","unstructured":"Hilkens NA, Casolla B, Leung TW, et al. Stroke[J]. Lancet. 2024;403(10446):2820\u201336.","journal-title":"Lancet"},{"issue":"1","key":"684_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","volume":"5","author":"BCV Campbell","year":"2019","unstructured":"Campbell BCV, De Silva DA, Macleod MR, et al. Ischaemic stroke[J]. Nat Rev Dis Primers. 2019;5(1):70.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"684_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S1474-4422(22)00519-1","volume":"22","author":"G Tsivgoulis","year":"2023","unstructured":"Tsivgoulis G, Katsanos AH, Sandset EC, et al. Thrombolysis for acute ischaemic stroke: current status and future perspectives[J]. Lancet Neurol. 2023;22(5):418\u201329.","journal-title":"Lancet Neurol"},{"issue":"24","key":"684_CR4","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","volume":"390","author":"S Li","year":"2024","unstructured":"Li S, Gu HQ, Li H, et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med. 2024;390(24):2264\u201373.","journal-title":"N Engl J Med"},{"issue":"3","key":"684_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2402980","volume":"391","author":"Y Xiong","year":"2024","unstructured":"Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for Ischemic Stroke at 45 to 24 Hours without Thrombectomy[J]. N Engl J Med. 2024;391(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"24","key":"684_CR6","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1001\/jama.2023.7827","volume":"329","author":"HS Chen","year":"2023","unstructured":"Chen HS, Cui Y, Zhou ZH, et al. Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the Aramis randomized clinical trial[J]. JAMA. 2023;329(24):2135\u201344.","journal-title":"JAMA"},{"issue":"11","key":"684_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"684_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials[J]. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"issue":"4","key":"684_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis[J]. PLoS Med. 2020;17(4): e1003082.","journal-title":"PLoS Med"},{"issue":"4","key":"684_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/STROKEAHA.109.572040","volume":"41","author":"EC Haley","year":"2010","unstructured":"Haley EC, Thompson JL, Grotta JC, et al. Phase IIB\/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial[J]. Stroke. 2010;41(4):707\u201311.","journal-title":"Stroke"},{"issue":"4","key":"684_CR11","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","volume":"14","author":"X Huang","year":"2015","unstructured":"Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study[J]. Lancet Neurol. 2015;14(4):368\u201376.","journal-title":"Lancet Neurol"},{"issue":"24","key":"684_CR12","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","volume":"374","author":"CS Anderson","year":"2016","unstructured":"Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke[J]. N Engl J Med. 2016;374(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"684_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","volume":"16","author":"N Logallo","year":"2017","unstructured":"Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial[J]. Lancet Neurol. 2017;16(10):781\u20138.","journal-title":"Lancet Neurol"},{"issue":"2","key":"684_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1161\/STROKEAHA.118.024223","volume":"50","author":"OM R\u00f8nning","year":"2019","unstructured":"R\u00f8nning OM, Logallo N, Thommessen B, et al. Tenecteplase versus alteplase between 3 and 4.5 hours in low national institutes of health stroke scale[J]. Stroke. 2019;50(2):498\u2013500.","journal-title":"Stroke"},{"issue":"6","key":"684_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S1474-4422(22)00171-5","volume":"21","author":"A Bivard","year":"2022","unstructured":"Bivard A, Zhao H, Churilov L, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial[J]. Lancet Neurol. 2022;21(6):520\u20137.","journal-title":"Lancet Neurol"},{"issue":"1 SUPPL","key":"684_CR16","first-page":"566","volume":"7","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, Thomassen L, Fromm A. Tenecteplase versus alteplase for management of acute ischemic stroke (nor-test 2 part A): a phase 3, randomised, open-label, blinded endpoint trial[J]. Eur Stroke J. 2022;7(1 SUPPL):566\u20137.","journal-title":"Eur Stroke J"},{"issue":"1","key":"684_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/svn-2021-000978","volume":"7","author":"S Li","year":"2022","unstructured":"Li S, Pan Y, Wang Z, et al. Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study[J]. Stroke Vasc Neurol. 2022;7(1):47\u201353.","journal-title":"Stroke Vasc Neurol"},{"issue":"10347","key":"684_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","volume":"400","author":"BK Menon","year":"2022","unstructured":"Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial[J]. Lancet. 2022;400(10347):161\u20139.","journal-title":"Lancet"},{"issue":"6","key":"684_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s12975-022-01012-9","volume":"13","author":"HQ Song","year":"2022","unstructured":"Song HQ, Wang Y, Ma QF, et al. Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a phase ila randomized clinical trial[J]. Transl Stroke Res. 2022;13(6):995\u20131004.","journal-title":"Transl Stroke Res"},{"issue":"7","key":"684_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25415","volume":"6","author":"H Song","year":"2023","unstructured":"Song H, Wang Y, Ma Q, et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial[J]. JAMA Netw Open. 2023;6(7): e2325415.","journal-title":"JAMA Netw Open"},{"issue":"10377","key":"684_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","volume":"401","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial[J]. Lancet. 2023;401(10377):645\u201354.","journal-title":"Lancet"},{"issue":"2","key":"684_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/STROKEAHA.123.045193","volume":"55","author":"S Li","year":"2024","unstructured":"Li S, Wang X, Jin A, et al. Safety and efficacy of reteplase versus alteplase for acute ischemic stroke: a phase 2 randomized controlled trial[J]. Stroke. 2024;55(2):366\u201375.","journal-title":"Stroke"},{"key":"684_CR23","unstructured":"Parsons M W, Yogendrakumar V, Churilov L, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4\u00b75 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial[J]. Lancet Neurol. 2024."},{"key":"684_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.14721","author":"X Meng","year":"2024","unstructured":"Meng X, Li S, Dai H, et al. Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL Randomized Clinical Trial[J]. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.14721.","journal-title":"JAMA"},{"issue":"3","key":"684_CR25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s13311-023-01391-3","volume":"20","author":"SE Miller","year":"2023","unstructured":"Miller SE, Warach SJ. Evolving thrombolytics: from alteplase to tenecteplase[J]. Neurotherapeutics. 2023;20(3):664\u201378.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"684_CR26","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1161\/STROKEAHA.119.025080","volume":"50","author":"AM Burgos","year":"2019","unstructured":"Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials[J]. Stroke. 2019;50(8):2156\u201362.","journal-title":"Stroke"},{"issue":"1","key":"684_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/23969873221150022","volume":"8","author":"S Alamowitch","year":"2023","unstructured":"Alamowitch S, Turc G, Palaiodimou L, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke[J]. Eur Stroke J. 2023;8(1):8\u201354.","journal-title":"Eur Stroke J"},{"issue":"8","key":"684_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107822","volume":"33","author":"K Srisurapanont","year":"2024","unstructured":"Srisurapanont K, Uawithya E, Dhanasomboon P, et al. Comparative efficacy and safety among different doses of tenecteplase for acute ischemic stroke: a systematic review and network meta-analysis[J]. J Stroke Cerebrovasc Dis. 2024;33(8): 107822.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"684_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","volume":"21","author":"CE Kvistad","year":"2022","unstructured":"Kvistad CE, N\u00e6ss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial[J]. Lancet Neurol. 2022;21(6):511\u20139.","journal-title":"Lancet Neurol"},{"issue":"10","key":"684_CR30","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1007\/s00415-022-11242-4","volume":"269","author":"P Ma","year":"2022","unstructured":"Ma P, Zhang Y, Chang L, et al. Tenecteplase vs. alteplase for the treatment of patients with acute ischemic stroke: a systematic review and meta-analysis[J]. J Neurol. 2022;269(10):5262\u201371.","journal-title":"J Neurol"},{"issue":"5","key":"684_CR31","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/STROKEAHA.122.042335","volume":"54","author":"D Rose","year":"2023","unstructured":"Rose D, Cavalier A, Kam W, et al. Complications of intravenous tenecteplase versus alteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis[J]. Stroke. 2023;54(5):1192\u2013204.","journal-title":"Stroke"},{"issue":"24","key":"684_CR32","doi-asserted-by":"publisher","first-page":"14889","DOI":"10.18632\/aging.205315","volume":"15","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wan TF, Chen J, et al. Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials[J]. Aging (Albany NY). 2023;15(24):14889\u201399.","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"684_CR33","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1161\/STROKEAHA.120.029749","volume":"51","author":"SJ Warach","year":"2020","unstructured":"Warach SJ, Dula AN, Milling TJ. Tenecteplase thrombolysis for acute ischemic stroke[J]. Stroke. 2020;51(11):3440\u201351.","journal-title":"Stroke"}],"updated-by":[{"DOI":"10.1007\/s40120-024-00709-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00684-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:30:53Z","timestamp":1741851053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00684-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00684-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40120-024-00709-3","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the Funding statement","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-024-00709-3","URL":"https:\/\/doi.org\/10.1007\/s40120-024-00709-3","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests and declare: support from the National Natural Science Foundation of China no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is a systematic review and network meta-analysis, which does not involve real-life patients or experimental animals; therefore, an ethical approval is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}